Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics |
| |
| Authors: | John G Csernansky John W Newcomer Karen Jackson Leon Lombrozo Kym F Faull Robert Zipursky Adolf Pfefferbaum William O Faustman |
| |
| Institution: | (1) Department of Psychiatry, Washington University School of Medicine, 63110 St. Louis, MO, USA;(2) Palo Alto DVA Medical Center, 94304 Palo Alto, CA, USA;(3) Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 94305 Stanford, CA, USA;(4) Present address: Department of Psychiatry, University of Toronto, Toronto, Canada;(5) Present address: Department of Psychiatry, University of California, Los Angeles, CA, USA |
| |
| Abstract: | Thirty-two acutely psychotic, male schizophrenic patients received raclopride, at 2, 6, or 12 mg/day, or haloperidol, 15 mg/day for 4 weeks after randomized, double-blind assignment. Twenty-six patients, including 19 who had been assigned one of the three doses of raclopride, completed the study. Raclopride, particularly at 12 mg/day, increased CSF homovanillic acid (HVA) at 4 weeks, and plasma HVA at 2 days, of treatment. The clinical response to raclopride was significantly correlated with plasma raclopride concentrations and baseline plasma HVA concentrations. Although raclopride is a substituted benzamide with atypical properties in animals, these results suggest that the doses of raclopride required for clinical efficacy and elevation of clinical indices of brain dopamine turnover are similar. |
| |
| Keywords: | Schizophrenia Antipsychotics Dopamine Raclopride |
| 本文献已被 SpringerLink 等数据库收录！ |
|
